Építés alatt – nem éles oldal
Belépés
Toborzás még nem indult1. fázis

First Study Evaluating the Safety and Dosage of YG-01 in Patients With Glioblastoma

A legfontosabb adatok

Ki végzi
YGION Biomedical GmbH
Hol
Ausztria1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toborzás még nem indult
Fázis
1. fázis
Résztvevők
15 fő, tervezett
Kezdés
2026. nov.
Várható befejezés
2029. nov.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • YG-01 Dose Level 1
  • YG-01 Dose Level 2
A regiszteradat frissítve
2026. november 12.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 35 feltétel megnézéseKevesebb

Egyéb feltételek

  • Pre-Production Screening inclusion criteria:
  • Patient provided written informed consent for study participation prior to initiation of any study specific activities/procedures
  • Histologically confirmed glioblastoma, IDH wild type, WHO CNS Grade 4 - classification according to WHO classification of CNS tumors 2021; patients of dose escalation cohorts are required to have undergone extensive tumor resection documented by post-surgical magnetic resonance imaging (MRI) demonstrating either no contrast enhancement or no greater than 1 cm x 1 cm x 1 cm volume of residual enhancing tumor
  • Age ≥18 years
  • ECOG 0-1
  • At least 4 manufacturable neoepitopes identified in a preceding tumor sample analysis study and availability of a manufacturing slot confirmed by the sponsor
  • Stable disease or no measurable disease according to local investigator assessment, following at least two MRI scans taken a minimum of 8 weeks apart, both conducted after the completion of standard 6 weeks radiotherapy with concurrent temozolomide; Pre-Therapy Screening inclusion criteria:
  • Having completed maintenance temozolomide therapy, received at least 4 cycles of temozolomide, and having an interval of at least 4 weeks between the last dose of temozolomide and the first administration of study medication
  • Stable disease or no measurable disease according to local investigator assessment, following an MRI scan taken after the completion of maintenance temozolomide therapy
  • Life expectancy > 3 months at start of study treatment as clinically determined by the investigator
  • ECOG 0-1
  • Availability of study medication confirmed by the sponsor
  • Absolute lymphocyte count (ALC) >0.75 x10\^9/L
  • No need for dexamethasone or any other steroid treatment within 1 week prior to baseline
  • No need for bevacizumab treatment within 1 week prior to baseline; Pre-Production Screening exclusion criteria:
  • Known HIV or active Hepatitis B or C infection, or active infections requiring oral or intravenous antibiotics or known infections that can cause a severe disease and pose a severe danger to lab personnel working on patient's blood or tissue
  • Concurrent participation in another interventional clinical trial studying a drug or treatment regimen
  • Clinically relevant autoimmune diseases (with the exception of autoimmune thyroid disease) that, in the investigator's judgement, may interfere with study participation
  • Immunosuppression, not related to treatment for glioblastoma
  • History of severe hypersensitivity reactions
  • Any condition that in the judgment of the investigator interferes with the probability that an individual patient may receive and benefit from YG-01 treatment (e.g., high risk of early disease progression / recurrence; immunocompromised status; anticipated compliance issues)
  • Clinically relevant illness or condition which may affect the patient's safety during the study or impede the patient's ability to complete the study, as assessed by the investigator
  • History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) unless the patient has been disease-free for the last 5 years
  • Pregnancy or breastfeeding; Pre-Therapy Screening exclusion criteria:
  • Abnormal (≥ grade 2 CTCAE v6.0) laboratory values for hematology, liver and renal function (serum creatinine)
  • HIV infection or active Hepatitis B or C infection, or active infections requiring oral or intravenous antibiotics or known infections that can cause a severe disease and pose a severe danger to lab personnel working on patient's blood or tissue
  • Concurrent participation in another interventional clinical trial studying a drug or treatment regimen
  • Clinically relevant autoimmune diseases (with the exception of autoimmune thyroid disease) that, in the investigator's judgement, may interfere with study participation
  • Any vaccination within 2 weeks prior to baseline
  • Immunosuppression, not related to prior treatment for glioblastoma
  • History of severe hypersensitivity reactions
  • Any condition that in the judgment of the investigator interferes with the probability that an individual patient may receive and benefit from YG-01 treatment (e.g., high risk of early disease progression / recurrence; immunocompromised status; anticipated compliance issues)
  • Clinically relevant illness or condition which may affect the patient's safety during the study or impede the patient's ability to complete the study, as assessed by the investigator
  • History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) unless the patient has been disease-free for the last 5 years
  • Pregnancy or breastfeeding

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

A feltételkérdéseket egy MI-rendszer írta a(z) NCT07930338 vizsgálathoz közzétett feltételekből. Szoftver ellenőrizte, nem orvos.

  • How old are you?

Ez a vizsgálat jelenleg itt érhető el: Ausztria.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a first-in-human, open-label, single-arm, dose-escalation Phase 1 clinical study evaluating the safety, tolerability, feasibility, and immunogenicity of the YG-01, a personalized neoantigen peptide-based cancer immunotherapy, in patients with diagnosed glioblastoma following standard-of-care therapy. The study will assess the safety and tolerability of repeated administrations of YG-01 and explore immune responses and clinical outcomes following treatment. The study includes sequential dose-escalation cohorts to evaluate the safety and tolerability of increasing dose levels of YG-01 and to identify a recommended dose for further clinical development.

A vizsgálat 2 csoportja

  • Dose Level 1A vizsgált kezelés

    Patients receive YG-01, a personalized neoantigen immunotherapy comprising patient-specific neoepitope peptides administered subcutaneously at Dose Level 1.

    Kezelés: YG-01 Dose Level 1

  • Dose Level 2A vizsgált kezelés

    Patients receive YG-01 at Dose Level 2 subcutaneously on the same schedule as Dose Level 1, started after Safety Committee review of Dose Level 1.

    Kezelés: YG-01 Dose Level 2

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
Phase 1 Dose-escalation Study of YG-01 in Patients With Glioblastoma
Kérdések a feltételekről
Forrás: NCT07930338: ki vehet részt
A regiszteradat frissítve
2026. november 12.